Fischer Medical Ventures Limited has announced updates to its board committee composition through a regulatory disclosure dated January 02, 2026. The medical technology company, registered in Visakhapatnam, Andhra Pradesh, provided detailed information about the structure and membership of its key governance committees.

Audit Committee Structure

The Audit Committee has been constituted with seven members, led by Mr. Khairy Jamaluddin Abu Bakar as Chairman. The committee composition reflects a strong independent oversight structure:

Nomination and Remuneration Committee

The Nomination and Remuneration Committee operates with a streamlined five-member structure, maintaining independent oversight for key personnel decisions:

Risk Management Committee Composition

The Risk Management Committee includes both board members and senior management personnel, providing comprehensive risk oversight across operational and strategic areas:

Corporate Governance Framework

The committee structures demonstrate Fischer Medical Ventures' commitment to robust corporate governance practices. The composition ensures appropriate balance between independent oversight and executive participation across all three committees. Mr. Khairy Jamaluddin Abu Bakar serves as Chairman for both the Audit Committee and Nomination and Remuneration Committee, while Ms. Svetlana Rao Raviwada chairs the Risk Management Committee.

The company operates from its registered office in the AP Medtech Zone, Visakhapatnam, with corporate offices located in Chennai, Tamil Nadu. The updated committee compositions reflect the company's ongoing efforts to maintain regulatory compliance and strengthen governance oversight mechanisms.

Fischer Medical Ventures , a prominent player in the medical technology sector, has reported a substantial surge in its financial performance for the second quarter of the fiscal year. The company's consolidated net profit skyrocketed to 139.00 million rupees, marking a remarkable 46-fold increase from the 3.00 million rupees reported in the same period last year.

Revenue Growth

The company's revenue witnessed a significant uptick, more than doubling to 863.00 million rupees from 397.00 million rupees year-over-year. This impressive growth in both top-line and bottom-line figures underscores Fischer Medical Ventures' strengthening market position and operational efficiency.

Financial Performance Overview

To provide a clearer picture of the company's financial achievements, here's a breakdown of the key figures:

The substantial growth in net profit, outpacing the revenue increase, suggests significant improvements in the company's cost management and operational efficiency.

Corporate Governance Updates

In a separate development, Fischer Medical Ventures has announced changes to its board of directors. The company has appointed Mr. Chan Sing En as an Additional Non-Executive Independent Director for a five-year term, effective October 28, 2025, subject to shareholder approval. Mr. Chan brings over three decades of experience in investment, private equity, and corporate finance across Southeast Asia and Australia.

Additionally, the board has recommended the appointment of Tan Sri Dato' Dr. Syed Jalaludin as an Independent Director, also for a five-year term, pending shareholder approval. Dr. Syed Jalaludin is a distinguished academician and corporate leader with extensive experience in higher education and various industries.

These appointments are expected to bring valuable expertise and strategic insights to Fischer Medical Ventures' board, potentially contributing to the company's continued growth and market expansion strategies.

Looking Ahead

While the company has not provided specific forward-looking statements, the substantial growth in both revenue and profit indicates a positive trajectory for Fischer Medical Ventures. The strategic additions to the board suggest a focus on strengthening governance and bringing in diverse industry perspectives, which may support the company's future growth initiatives.

Investors and stakeholders will likely be watching closely to see if the company can maintain this growth momentum in the coming quarters, especially given the dynamic nature of the medical technology sector.